Opinion|Videos|July 2, 2024
RSV Vaccine Efficacy in Pregnancy
Author(s)Carrie Koenigsfeld, PharmD, FAPhA
Carrie Koenigsfeld, PharmD, FAPhA, highlights the main findings from the MATISSE trial, which evaluated the safety and efficacy of a non-adjuvanted RSV vaccine administered to pregnant women, presenting data that suggests the vaccine's effectiveness in preventing severe RSV in infants and discussing the observed adverse events in both mothers and infants.
Advertisement
Episodes in this series
- What were the key results from the
MATISSE trial regarding the safety and efficacy of the non-adjuvanted vaccine in pregnant women?
- Efficacy in preventing severe RSV in infants
- Adverse effects in maternal and infant subjects
- Trial limitations: no high-risk pregnancies
Advertisement
Related to this article
The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
The once-daily device, bioequivalent to the existing prefilled syringe, gives adults with AChR antibody-positive generalized MG a second self-injection option.
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Neither the lipoprotein(a) [Lp(a)]–lowering antisense oligonucleotide nor the IL-6 inhibitor cut CV events in phase 3, but patients with high Lp(a) may still bring questions to pharmacists.
Pharmacists make a difference in patients’ lives through MTM services.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Finerenone Expands MRA Options as Pharmacists Address Underrecognized HFpEF
2
Researchers Target Viral Fusion for Universal Flu, HIV Vaccines
3
Finerenone in Heart Failure: Evidence and Practice a Year Later
4
FDA Approves Zilucoplan Autoinjector for Myasthenia Gravis
5